Our Blog
Keep up to date with our latest conversations, discussions and stories – together we can transform clinical cancer care
The development of a highly sensitive test for detecting residual disease and recurrence in cancer patients
Event expiration date display - 21 JUL 2020
As cells die in our body, they release DNA into our blood stream. This cell free DNA (cfDNA) can come from many sources, including healthy cells such as white blood cells. In individuals with ... read more
AACR 2020 Summary: Demonstrating a sensitive and specific personalized assay to detect residual disease and recurrence
Event expiration date display - 07 JUL 2020
This year’s annual meeting of the American Association for Cancer Research (AACR) was converted into an entirely virtual experience focused on clinical data as a result of the COVID-19 pandemic. ... read more
Sophie Hackinger in our bioinformatics team discusses the reasons she joined Inivata – I wanted to build products that would have a direct impact on patients’ lives.
Event expiration date display - 20 APR 2020
I started out with an undergraduate degree in biomedical sciences, which was more wet lab focused. What really fascinated me about human biology was how the combination of multiple genetic and ... read more
Anna Farne, Senior Software Developer at Inivata tells us more about how her role in software development is helping transforming the lives of cancer patients around the world.
Event expiration date display - 7 APR 2020
During my first role working as a lab technician I became interested in IT and how it fits into a science and research environment. There were nice software tools for data analysis, LIMS systems ... read more
Tim Forshew, Co-founder and Head of Science and Innovation at Inivata shares his thoughts on a recent publication from groups at Dana-Farber, Broad Institute and Boston University that demonstrate the value of personalized assays for detecting ctDNA with high sensitivity.
Event expiration date display - 1 APR 2020
Thoughts on Parsons et al 2020 – a new study on the value of personalized ctDNA assays for residual disease and recurrence detection read more
Warren Emmett, Computational Genomics Team Lead at Inivata talks about how his role in bioinformatics is helping lung cancer patients.
Event expiration date display - 04 MAR 2020
I started out with an undergrad in Human Genetics and after doing a tutorial on the BLAST algorithm I fell in love with bioinformatics, and the potential it held for changing biology. After ... read more
The critical importance of sensitivity and how inivata’s technology is expanding the reach of liquid biopsy into new clinical and pharmaceutical applications.
Event expiration date display - 28 JAN 2020
Antony Newton, VP Business Development, talks about the critical importance of sensitivity and how Inivata’s technology is expanding the reach of liquid biopsy into new clinical and ... read more
Pioneering and focused on making a difference to cancer management – liquid biopsy.
Event expiration date display - 13 NOV 2019
Liquid biopsy offers the potential to transform the way physicians manage cancer and deliver significant benefits to patients by guiding and personalizing treatment, monitoring response and ... read more
A personal passion for innovation and to make a difference to cancer care.
Event expiration date display - 31 OCT 2019
Nitzan Rosenfeld, CSO and Co-founder, Inivata talks about the personal story behind his scientific career and his path to making fundamental breakthroughs in liquid biopsyWhat drove you towards ... read more
